Delayed Puberty Phenotype Observed in Noonan Syndrome Is More Pronounced in Girls than Boys

Carregando...
Imagem de Miniatura
Citações na Scopus
3
Tipo de produção
article
Data de publicação
2022
Título da Revista
ISSN da Revista
Título do Volume
Editora
KARGER
Citação
HORMONE RESEARCH IN PAEDIATRICS, v.95, n.1, p.51-61, 2022
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Introduction: Pubertal delay is described as one of the clinical features in Noonan syndrome (NS) and it may be one of the factors causing short adult height in those patients. The present study aimed at characterizing pubertal development in NS and identifying pubertal delay predictors. Methods: We analyzed 133 individuals with a molecular diagnosis of NS and clinical puberty evaluation. We characterized delayed puberty as pubertal onset after 12 years in girls and 13.5 years in boys, according to parameters of the Brazilian population. To investigate its predictors, we correlated the age at onset of puberty with several characteristics and genotype in a multilevel regression model. For comprehending pubertal development in NS, we assessed age and anthropometric measures at each Tanner stage and adult age. Results: The mean age at puberty onset for girls was 11.9 +/- 1.9 years and for boys, 12.5 +/- 1.7 years, significantly later than the Brazilian population (p = 0.025; p < 0.001). Girls (49.1%) presented delayed puberty more frequently than boys (27.9%, p = 0.031). Body mass index standard deviation scores (SDS) and insulin growth factor 1 SDS at puberty onset significantly predicted later puberty entry. Height gain from the onset of puberty to adult height was lower in children with pubertal delay. Conclusion: Pubertal delay is characteristically found in children with NS, more frequently in females. The low weight of patients with NS could modulate the age of puberty, just as the increase in overweight/obesity in the general population has shown an effect on reducing the age of onset of puberty.
Palavras-chave
Noonan syndrome, Pubertal delay, Pubertal development, Pubertal disorders
Referências
  1. Aksglaede L, 2009, PEDIATRICS, V123, pE932, DOI 10.1542/peds.2008-2491
  2. Ankarberg-Lindgren C, 2011, EUR J ENDOCRINOL, V165, P137, DOI 10.1530/EJE-11-0092
  3. Artoni A, 2014, PEDIATRICS, V133, pE1299, DOI 10.1542/peds.2013-3251
  4. Bayer LM., 1959, CALIF MED, V91, P53
  5. Bertelloni S, 2013, HORM-INT J ENDOCRINO, V12, P86, DOI 10.1007/BF03401289
  6. Biro FM, 2016, ENDOCR DEV, V29, P122, DOI 10.1159/000438881
  7. Busch AS, 2020, J CLIN ENDOCR METAB, V105, DOI 10.1210/clinem/dgz222
  8. Cannarella R, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22052445
  9. Carrascosa A, 2018, AN PEDIATR, V89, P144, DOI 10.1016/j.anpedi.2017.11.018
  10. da Silva FM, 2016, AM J MED GENET A, V170, P1525, DOI 10.1002/ajmg.a.37639
  11. Davison KK, 2003, PEDIATRICS, V111, P815, DOI 10.1542/peds.111.4.815
  12. Domene S, 2020, MOL CELL ENDOCRINOL, V518, DOI 10.1016/j.mce.2020.111006
  13. Du X, 2003, EUR J CLIN NUTR, V57, P693, DOI 10.1038/sj.ejcn.1601599
  14. Jongmans M, 2004, HORM RES, V62, P56, DOI 10.1159/000080500
  15. Jorge AAL, 2009, HORM RES, V71, P185, DOI 10.1159/000201106
  16. Kuczmarski RJ, 2000, VITAL HLTH STAT, V11, P1, DOI 10.1016/J.BBRC.2015.06.114
  17. Laron Z, 2004, J CLIN ENDOCR METAB, V89, P1031, DOI 10.1210/jc.2003-031033
  18. Lee JM, 2007, PEDIATRICS, V119, pE624, DOI 10.1542/peds.2006-2188
  19. Feibelmann TCM, 2021, REV PAUL PEDIATR, V39, DOI 10.1590/1984-0462/2021/39/2019109
  20. Feibelmann TCM, 2015, ARCH ENDOCRIN METAB, V59, P105, DOI 10.1590/2359-3997000000021
  21. Malaquias AC, 2021, MOL CELL ENDOCRINOL, V519, DOI 10.1016/j.mce.2020.111040
  22. Malaquias AC, 2012, AM J MED GENET A, V158A, P2700, DOI 10.1002/ajmg.a.35519
  23. Marcovecchio ML, 2013, WORLD REV NUTR DIET, V106, P135, DOI 10.1159/000342545
  24. MARSHALL WA, 1969, ARCH DIS CHILD, V44, P291, DOI 10.1136/adc.44.235.291
  25. MARSHALL WA, 1970, ARCH DIS CHILD, V45, P13, DOI 10.1136/adc.45.239.13
  26. Noordam C, 2001, CLIN ENDOCRINOL, V54, P53, DOI 10.1046/j.1365-2265.2001.01188.x
  27. Oehme NHB, 2021, ANDROLOGY-US, V9, P837, DOI 10.1111/andr.12985
  28. Pereira A, 2021, J CLIN ENDOCR METAB, V106, P1352, DOI 10.1210/clinem/dgab064
  29. Pierpont EI, 2009, GENES BRAIN BEHAV, V8, P275, DOI 10.1111/j.1601-183X.2008.00469.x
  30. RANKE MB, 1988, EUR J PEDIATR, V148, P220, DOI 10.1007/BF00441408
  31. Roberts AE, 2013, LANCET, V381, P333, DOI 10.1016/S0140-6736(12)61023-X
  32. Romano AA, 2010, PEDIATRICS, V126, P746, DOI 10.1542/peds.2009-3207
  33. Romano AA, 2009, J CLIN ENDOCR METAB, V94, P2338, DOI 10.1210/jc.2008-2094
  34. Schubbert S, 2007, NAT REV CANCER, V7, P295, DOI 10.1038/nrc2109
  35. SHARLAND M, 1992, ARCH DIS CHILD, V67, P178, DOI 10.1136/adc.67.2.178
  36. Shaw AC, 2007, ARCH DIS CHILD, V92, P128, DOI 10.1136/adc.2006.104547
  37. Tajan M, 2018, ENDOCR REV, V39, P676, DOI 10.1210/er.2017-00232
  38. Tajan M, 2018, HUM MOL GENET, V27, P2276, DOI 10.1093/hmg/ddy133
  39. Tamburrino F, 2015, AM J MED GENET A, V167, P2786, DOI 10.1002/ajmg.a.37260
  40. Tartaglia M, 2002, AM J HUM GENET, V70, P1555, DOI 10.1086/340847
  41. Tartaglia M, 2007, NAT GENET, V39, P75, DOI 10.1038/ng1939
  42. THEINTZ G, 1982, ARCH DIS CHILD, V57, P13
  43. Upners EN, 2021, PEDIATR RES, V90, P176, DOI 10.1038/s41390-020-01215-6
  44. USHER R, 1969, J PEDIATR-US, V74, P901, DOI 10.1016/S0022-3476(69)80224-6
  45. Wenger BM, 2021, GENET MED, V23, P94, DOI 10.1038/s41436-020-00973-2
  46. Yart A, 2018, CURR OPIN ENDOCRINOL, V25, P67, DOI 10.1097/MED.0000000000000380
  47. Zenker M, 2004, J PEDIATR-US, V144, P368, DOI 10.1016/j.jpeds.2003.11.032